Abstract
Purpose:
The purpose of this study was to describe a method to determine the position of the preferred retinal locus (PRL).
Methods:
Cross-sectional data were obtained prospectively. Microperimetry was completed with the Macular Integrity Assessment (MAIA) under mesopic testing conditions. Spectral domain optical coherence tomography (SD-OCT) was acquired with the Spectralis SD-OCT system. The printout of the MAIA containing the PRL and both the horizontal and vertical transfoveal scans were interpolated in Adobe Photoshop, which was used to calculate the foveal center (FC) and to create a custom ruler to measure the distance from the foveal center (DFC) and the distance between PRL (DPRL). The methodology was tested by two independent graders in participants of a natural history study for KCNV2-associated retinopathy.
Results:
Twenty-two eyes of 12 subjects were analyzed at a mean age of 31.9 years (range = 11–54 years, SD = ±14.3). The mean DFC and DPRL was 1398 µm (range = 182.8–2896, SD = ±755.4), and 751.4 µm (range = 144.5–1493.3, SD = ±458.3) in the right eyes, and 1104 µm (range = 341.8–2513, SD = ±653.78) and 742.5 µm (range = 120–1918, SD = ±586.5) in the left eyes, respectively. There was no significant interocular correlation of DFC (r = −0.036, P = 0.92) or DPRL (r = 0.41, P = 0.26), or between the two variables in the right (r = 0.519, P = 0.084) and left eyes (r = 0.014, P = 0.97). These suggest that DPRL may not be related to the location of eccentric fixation and that the values of either eye are independent of each other.
Conclusions:
Our data suggest that these are reliable parameters, which could be of relevance in the context of clinical trials. The sample size is small and its correlation with other functional and structural outcomes remains to be explored, but these findings provide a framework for further development.
Translational Relevance:
This work bridges the distance between basic science and clinical care by providing a reliable and replicable method to quantify the preferred retinal locus of patients with eccentric fixation.
The Macular Integrity Assessment (MAIA; CenterVue, Padova, Italy) was used to assess mesopic retinal sensitivity.
Figure 1 demonstrates the grid used for the patients with each of the 68 stimuli numbers.
The test was conducted monocularly in a darkened room without pharmacological mydriasis. Prior to the test, the subjects were dark adapted for 20 minutes. The contralateral eye not being tested was occluded – with the right eye being tested first in each case. A Goldmann size III stimulus with duration of 200 ms was used in a 4–2 threshold strategy and background luminance of 1.27 cd/m2. The fixation target was a red circle, as standardized by the MAIA device. The central 10 degrees were tested using a standard 10–2 grid consisting of 68 points with test points spaced 2 degrees apart. This device has a dynamic range of 36 decibels (dB). Due to eccentric fixation, if necessary (e.g. if the PRL was too far from the posterior pole), the grid position was manually changed to the anatomic fovea by using the spectral domain optical coherence tomography (SD-OCT) as reference. This was done to test the greatest possible number of points in the central retina. The reliability criterion chosen for the MAIA was a threshold of fixation loss ≤ 15%, with repetition of the test should it exceed this value. Catch trials are not available in the MAIA, hence this is the only reliability index available for the device.
The PRL is automatically assessed by the MAIA, which provides accurate and objective information regarding retinal location and stability of fixation. It tracks eye movements 25 times per second for 10 seconds and plots the resulting distribution over the scanning laser ophthalmoscopy (SLO) image. Two main PRL reference points, known as PRL_initial (PRLi) and PRL_final (PRLf), are calculated at the center of the cluster of fixation points. The former defines the center of the stimuli grid (after the initial 10 seconds of examination), whereas the latter is found at the end of the examination and serves as the reference point used to calculate fixation stability. The PRLf is invariably calculated at the end of the test and is dependent on the total test time of each subject. MAIA calculates fixation stability in two different ways:
- 1. As the area of a 2-dimensional ellipse –BCEA – which encompasses the cloud of fixation points based on standard deviations of the vertical and horizontal eye positions during the fixation attempt, and
- 2. By calculating the percentage of fixation points located within a distance of 1 (P1) and 2 degrees (P2) from the reference point (PRLf), respectively: (i) if more than 75% of the fixation points are located within P1, the fixation is classified as “stable”; (ii) if less than 75% are within the P1, but more than 75% within the P2, it is classified as “relatively unstable”; and (iii) if less than 75% are located within the P2, the fixation is classified as “unstable.” Both the BCEA and the PRLf (cyan lozenge) are shown in Figure 1.
Although these two methods essentially constitute two ways of calculating a similar outcome, unlike the BCEA, the PRLi and PRLf provide a more “pinpoint” location to the fixation, particularly the PRLf, given it accurately summarizes and represents the center of the fixation in context with the retinal imaging, thus facilitating the visualization of the PRL.
All subjects were imaged using the Spectralis SD-OCT system (Heidelberg, Engineering Inc., Heidelberg, Germany). The test was conducted in a darkened room after pupil dilation with 1 drop of 2.5% phenylephrine and 1% tropicamide. Twenty degrees square volume scans were obtained, both in the vertical and horizontal axis (193 B-scans), with ART off. Subsequently, 20-degree wide single line scans were obtained vertically and horizontally. In the presence of significant nystagmus, the number of averaged images were reduced.
Fundus autofluorescence (FAF) was then undertaken for each eye. The autofluorescence mode has a 488 nm excitation and a beam power of less than 260 microwatts. Thirty degrees square images were obtained.
In the present study, the tests were standardized following well described protocols and acquired prospectively by an expert technical team. Similarly, these data suggest that these are reliable parameters, which could be of relevance in the context of clinical trials. However, the sample size is small and only to be taken as an example of this methods’ application, with a larger and more heterogenous dataset being necessary to extrapolate any conclusions regarding the location of the PRL in patients with central retinal disease. Its correlation with other functional and structural outcomes remains to be explored. Despite these limitations, these findings provide a framework for further development.
Michel Michaelides is supported by grants from the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, and Moorfields Eye Charity. Michel Michaelides is supported by The Wellcome Trust (099173/Z/12/Z) and the Foundation Fighting Blindness. Thales A. C. de Guimaraes is supported by a Clinical Research Fellowship Award from Foundation Fighting Blindness (CD-CL-0623-0843-UCL). James Bainbridge is supported by grants from the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, and Moorfields Eye Charity.
Author Contributions: T.A.C.G. was responsible for conceptualization, images, methodology, and writing. T.A.C.G., and A.K. were responsible for data collection, curation, writing, and draft review. J.B. and M.M. were responsible for conceptualization and critical draft review. All authors contributed to the main manuscript writing and review.
Disclosure: T.A.C. de Guimaraes, None; A. Kalitzeos, None; J. Bainbridge, None; M. Michaelides, None